Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia

Journal of Infection and Chemotherapy

Volumn 18, Issue 5, 2012, Pages 722-728

  Ainoda, Yusuke ^a   Hirai, Yuji ^a   Fujita, Takahiro ^a   Isoda, Noriko ^b   Totsuka, Kyoichi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

Author keywords

Intubation; Mortality; Non HIV Pneumocystis jirovecii pneumonia (non HIV PCP); Treatment delay

Indexed keywords

AZATHIOPRINE; BETA GLUCAN; BETAMETHASONE; C REACTIVE PROTEIN; COTRIMOXAZOLE; DEXAMETHASONE; LACTATE DEHYDROGENASE; MEPREDNISONE; PREDNISOLONE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DYSPNEA; FEMALE; FEVER; HEMODIALYSIS; HUMAN; INTUBATION; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MORTALITY; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEX RATIO; SURVIVAL RATE; THERAPY DELAY; TREATMENT DURATION;

EID: 84871360839     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0408-5     Document Type: Article

References (31)

1. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis. 2002;34:1098-107.
2. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71:5-13.
3. Wang J, Wright TW, Gigliotti F. Immune modulation as adjunctive therapy for Pneumocystis pneumonia. Interdiscipl Perspect Infect Dis. 2011;. doi:10.1155/2011/918038.
4. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of Pneumocystis colonization. J Infect Dis. 2008;197: 10-7.
5. Thomas CF Jr., Limper AH. Pneumocystis pneumonia. N Engl J Med. 2004;350:2487-98.
6. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest. 2000;118:704-11.
7. Enomoto T, Azuma A, Kohno A, Kaneko K, Saito H, Kametaka M, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without HIV infection. Respirology. 2010;15:126-31.
8. Wang XL, Wang XL, Wei W, An CL. Retrospective study of Pneumocystis pneumonia over half a century in mainland China. J Med Microbiol. 2011;60:631-8.
9. Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother. 2007;13:1-7.
10. Catherinot E, Lanternier F, Bougnoux ME, Lecuit M, Couderc LJ, Lortholary O. Pneumocystis jirovecii pneumonia. Infect Dis Clin N Am. 2010;24:107-38.
11. Matsumura Y, Shindo Y, Iinuma Y, Yamamoto M, Shirano M, Matsushima A, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis. 2011;11:76.
12. Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M, Dary M, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2002;21:523-31.
13. Aoki Y, Iwamoto M, Kamata Y, Nagashima T, Yoshio T, Okazaki H, et al. Prognostic indicators related to death in patients with Pneumocystis pneumonia associated with collagen vascular diseases. Rheumatol Int. 2009;29:1327-30.
14. Tokuda H, Sakai F, Yamada H, Johkoh T, Imamura A, Dohi M, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med. 2008;47:915-23.
15. Bollée G, Sarfati C, Thiéry G, Bergeron A, de Miranda S, Menotti J, et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest. 2007;132:1305-10.
16. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med. 2010;49:273-81.
17. Atzori C, Agostoni F, Angeli E, Mainini A, Orlando G, Cargnel A. Combined use of blood and oropharyngeal samples for noninvasive diagnosis of Pneumocystis carinii pneumonia using the polymerase chain reaction. Eur J Clin Microbiol Infect Dis. 1998;17:241-6.
18. Leigh TR, Wakefield AE, Peters SE, Hopkin JM, Collins JV. Comparison of DNA amplification and immunofluorescence for detecting Pneumocystis carinii in patients receiving immunosuppressive therapy. Transplantation. 1992;54:468-70.
19. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, Takeuchi T, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. 2007;131:1173-80.
20. Watanabe T, Yasuoka A, Tanuma J, Yazaki H, Honda H, Tsukada K, et al. Serum (1?3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis. 2009;49:1128-31.
21. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospitalacquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
22. Arend SM, Kroon FP, van't Wout JW. Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases. Arch Intern Med. 1995;155:2436-41.
23. Wachter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitovsky AA. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA. 1995;273:230-5.
24. Buttgereit F, Burmester GR, Straub RH, Seibel MJ, Zhou H. Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum. 2011;63:1-9.
25. Nakamura H, Tateyama M, Tasato D, Haranaga S, Yara S, Higa F, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med. 2009;48: 195-202.
26. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007;3:CD005590.
27. Rabodonirina M, Vanhems P, Couray-Targe S, Gillibert RP, Ganne C, Nizard N, et al. Molecular evidence of interhuman transmission of Pneumocystis pneumonia among renal transplant recipients hospitalised with HIV-infected patients. Emerg Infect Dis. 2004;10:1766-73.
28. Hocker B, Wendt C, Nahimana A, Tonshoff B, Hauser PM. Molecular evidence of Pneumocystis transmission in pediatric transplant unit. Emerg Infect Dis. 2005;11:330-2.
29. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, Berger SP, Gelinck LB, van Houwelingen HC, et al. An outbreak of Pneumocystis jirovecii pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental sourceClin Infect Dis. 2007;44: 1143-9.
30. Schmoldt S, Schuhegger R, Wendler T, Huber I, Sollner H, Hogardt M, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol. 2008;46:966-71.
31. Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jirovecii pneumonia in renal transplant recipients: P. jirovecii is contagious to the susceptible host. Transplantation. 2009;88:380-5.